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Abstract Vascular endothelial growth factor (VEGF) is a
potent angiogenic factor, which also has neuroprotective
activity. In view of these dual actions on vessels and
neurons, we were interested whether VEGF promotes long
distance axonal plasticity in the ischemic brain. Herein, we
show that VEGF promotes neurological stroke recovery in
mice when delivered in a delayed way starting 3 days after
middle cerebral artery occlusion. Using anterograde tract-
tracing experiments that we combined with histochemical
and molecular biological studies, we demonstrate that
although VEGF promoted angiogenesis predominantly in
the ischemic hemisphere, pronounced axonal sprouting was
induced by VEGF in the contralesional, but not the
ipsilesional corticobulbar system. Corticobulbar plasticity
was accompanied by the deactivation of the matrix
metalloproteinase MMP9 in the lesioned hemisphere and
the transient downregulation of the axonal growth inhibi-
tors NG2 proteoglycan and brevican and the guidance
molecules ephrin B1/2 in the contralesional hemisphere.
The regulation of matrix proteinases, growth inhibitors,
and guidance molecules offers insights how brain plasticity
is controlled in the ischemic brain.
Keywords Anterograde tract tracing  Axonal sprouting 
Ischemic stroke  Guidance cues 
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Introduction
Subsequent to a stroke, the brain tissue undergoes profound
remodeling processes composed of finely tuned cell–cell
and cell–extracellular matrix (ECM) interactions [35],
aiming at the reconstitution of a functional neurovascular
system. In the vicinity of a stroke lesion, new vessels are
formed [11, 35]. Besides this, the inhibition of axonal
growth, which is characteristic to the adult mammalian
central nervous system, is suspended [4, 32]. This suggests
that in response to stroke ontogenic protein expression
programs are reactivated [5].
Vascular endothelial growth factor (VEGF) is a pleio-
tropic growth factor that is physiologically expressed in the
brain mainly by astrocytes and microglia together with its
receptors VEGFR2 and VEGFR1 that are predominantly
found on endothelial cells [8, 11, 17]. Upon hypoxia and
ischemia, VEGF and its receptors are rapidly induced
within hours on neurons and glial cells [11]. In the acute
phase of ischemic stroke, VEGF exerts multiple actions in
the peri-infarct region that include the promotion of neu-
ronal survival [23, 29], angiogenesis [29, 34], and neural
progenitor cell proliferation, migration and differentiation
[23, 30].
Recent data in non-human primates subjected to cir-
cumscribed infarcts of the motor cortex showed that
besides associating with neurons throughout the lesioned
hemisphere VEGF can also be found in injury-remote
neurons of the contralateral motor cortex [21]. Not only
VEGF, but also its receptor VEGFR2 is de novo expressed
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on lesion-remote motor cortical neurons [22]. This obser-
vation raised the question about VEGF’s role in the
reorganization of ischemic brain tissue. Lesion-remote
plasticity is well established in the meantime to contribute
to neurological recovery after stroke in rodents [18, 32] and
human patients [9, 27].
In view of the unique activities of VEGF in stimulating
the survival and proliferation of neurons and endothelial
cells, we were interested to know whether VEGF influ-
ences long distance axonal plasticity in the ischemic brain.
For this purpose, we performed a comprehensive analysis
in mice submitted to focal cerebral ischemia, characteriz-
ing effects of a post-acute VEGF delivery on neurological
recovery, neuronal survival, angiogenesis, and pyramidal
tract plasticity using behavioral studies, anterograde tract
tracing, histochemical and molecular biological techniques.
Materials and methods
Animal groups
Experiments were performed in accordance with National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals with local government approval
(Bezirksregierung Düsseldorf, TSG966/08). A total of 124
male C57Bl6/j mice (8–10 weeks, 23–25 g) were submitted
to 30 min of left-sided middle cerebral artery occlusion
(MCAO). At 72 h post ischemia, mini-osmotic pumps were
implanted into the left-sided lateral ventricle. The pumps
were filled with 0.9% NaCl (vehicle) or VEGF (0.004 or
0.02 lg/day diluted in 0.9% NaCl). As such, mice were
randomly selected from groups housed together in the same
cages that had undergone MCAO on the same day. Animal
experiments and behavioral tests were done by two different
persons, ruling out data bias. The pumps were left in place
during the subsequent 4 weeks and then removed (Fig. 1).
Of 124 mice, three mice were excluded from the study
because of respiratory abnormalities that developed during
the first 3 days after MCAO. After the implantation of
mini-osmotic pumps, five mice had to be removed because
of complications related to pump insertion. In the following
4 weeks, four mice opened their wound and manipulated
their pump. These animals also had to be killed. There were
no differences between groups regarding animal dropouts.
A total of 112 mice were further analyzed.
One set of mice were used for studies on functional
neurological recovery and for analysis of axonal plasticity
(n = 10 animals per group). For that purpose, mice
received anterograde tract tracer injections in both frontal
Fig. 1 Experimental procedures and animal groups. Mice submitted
to MCAO that were treated with VEGF or vehicle from 3–30 dpi
were used for a tract-tracing studies and behavioral analysis, b protein
analysis studies (western blots, gelatin zymography) and c conven-
tional histochemical and immunohistochemical studies. Numbers of
animals evaluated for each group and time-point of animal killing are
shown. On the far right, the rostrocaudal level, from which brain
sections and tissue samples were harvested, is also illustrated. In d,
non-ischemic animals prepared for various experiments in (a)–(c) are
summarized (see also ‘‘Materials and methods’’ section). CB, Cascade
blue, BDA, biotinylated dextran amine, dpi, days post ischemia
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motor cortices at 42 days after the stroke. Ten days later,
the animals were killed (Fig. 1a).
Additional sets of mice were subjected to 30 min
MCAO according to the same protocol, followed by
implantation of intraventricular pumps filled with vehicle
or VEGF (0.02 lg/day in 0.9% NaCl) 3 days later. These
animals were killed (1) at 3, 14, 30, or 42 days (used for
protein analysis studies, i.e., western blots and gelatin
zymography) (Fig. 1b) and (2) at 3, 14, 30, or 52 days
(used for histochemistry) (Fig. 1c) after the stroke (n = 4
animals per group, survival time and set of animals).
For tract-tracing studies, protein analysis, and histo-
chemistry, additional sham-operated mice receiving pump
implantations (filled with vehicle, n = 4 per group)
(Fig. 1d) were also prepared. In sham-operated animals,
the vehicle-filled pumps were implanted as specified. The
latter sham-operated and untreated mice were killed at 3,
14, 30, 42, and 52 days post-surgery.
Induction of focal cerebral ischemia
The animals were anesthetized with 1% isoflurane (30%
O2, remainder N2O). Rectal temperature was maintained
between 36.5 and 37.0C using a feedback-controlled
heating system. Cerebral blood flow was analyzed by laser
Doppler flow (LDF) recordings. Focal cerebral ischemia
was induced using an intraluminal filament technique [7,
13, 33] Shortly, a midline neck incision was made, and the
left common and external carotid arteries were isolated and
ligated. A microvascular clip was temporarily placed on
the internal carotid artery. A silicon-resin-coated nylon
monofilament was introduced through a small incision into
the common carotid artery and advanced to the carotid
bifurcation for MCAO. 30 min later, reperfusion was
initiated by monofilament removal. Laser Doppler flow
changes were monitored up to 30 min after reperfusion
onset. In sham-operated animals, a surgical intervention
was performed, in which the neck was opened and the
common carotid artery was exposed, but left intact, while
LDF recordings were performed. After the surgery, wounds
were carefully sutured, anesthesia was discontinued and the
animals were placed back into their cages.
Intraventricular pump implantation
Three days after surgery animals were re-anesthetized with
1% isofluran (30% O2, remainder N2O) and cannulae
linked to mini-osmotic pumps (Alzet 2004 or 2002; Alzet,
Cupertino, CA, USA) filled with 0.9% NaCl or VEGF
(0.004 lg or 0.02 lg/day in 0.9% NaCl) were implanted
into the left-sided lateral ventricle through a bur hole [14].
These pumps were left in place for up to 4 weeks and then
removed.
Functional neurological tests
Functional neurological recovery was assessed using a
battery of tests at baseline and on days 3, 14 and 42 after
MCAO.
Grip strength test: The grip strength test consists of a
spring balance coupled with a Newtonmeter (Medio-Line
Spring Scale, metric, 300 g, Pesola AG, Switzerland) that is
attached to a triangular steel wire which the animal
instinctively grasps. When pulled by the tail, the animal
exerts force on the steel wire [25]. The grip strength was
evaluated at the right paretic forepaw, the left non-paretic
forepaw being wrapped with adhesive tape. Grip strength
was evaluated five times on occasion of each test, for which
mean values were calculated. From these data, percentage
values (post-ischemic vs. pre-ischemic) were computed.
Pre-ischemic results did not differ between groups.
RotaRod test: The RotaRod consists of a rotating drum
with a speed accelerating from 6 to 40 rpm (Ugo Basile,
model 47600, Comerio, Italy), which allows to assess
motor coordination skills [24]. Maximum speed is reached
after 245 s, and the time at which the animal drops off the
drum is evaluated (maximum testing time 300 s). Mea-
surements were performed five times each on the same
occasion when grip strength was evaluated. For all five
measurements, mean values were computed, from which
percentage values (post-ischemic vs. pre-ischemic) were
calculated. Pre-ischemic data did not differ between
groups.
Delivery of cascade blue-labeled dextran amine (CB)
and biotinylated dextran amine (BDA)
The anterograde tract tracer BDA has previously been used
to evaluate pyramidal tract plasticity contralateral to the
stroke in rats submitted to permanent focal cerebral
ischemia [37]. We recently adopted this method to mice,
administering two different tracers, CB and BDA, in the
motor cortex both ipsilateral (CB) and contralateral (BDA)
to the stroke [19]. For this purpose, cranial bur holes were
drilled 0.5 mm rostral and 2.5 mm lateral to the bregma,
via which deposits of 10% BDA or 10% CB (both
10,000 MW; Invitrogen, Darmstadt, Germany), diluted in
0.01 M phosphate-buffered saline (PBS) at pH 7.2) were
placed into the motor cortex by means of microsyringe
injections 6 weeks after MCAO. As such, a total volume of
2.1 ll tracer was administered to each animal, which was
injected in three equal deposits that were located rostrally,
medially and caudally of the bur hole inside the motor
cortex. For this purpose, the syringe was inserted into the
brain at angles of 45, 90 and 135 against the midline.
Ten days after the tracer injection, the mice were tran-
scardially perfused with 0.1 M PBS containing 100 I.U.
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heparin followed by 4% paraformaldehyde in 0.1 M PBS.
Brains were removed and post-fixed overnight in 4%
paraformaldehyde in 0.1 M PBS and 5% sucrose and
cryoprotected in increasing concentrations of sucrose (5,
10, and 30%) over 3 days. The tissue was then frozen with
isopentane and cut into 20 and 40 lm thick coronal cryo-
stat sections that were used for conventional and tract-
tracing histochemistry.
Conventional histochemical studies
For conventional immunohistochemistry, animals that were
transcardially perfused with 0.9% NaCl at 14, 30 and 52 dpi
(days post ischemia) were used. The brains were frozen on
dry-ice and cut on a cryostat into 20 lm coronal sections
[14]. Brain sections from the level of the bregma (i.e.,
midstriatum) were fixed in 4% PFA in 0.1 M PBS, rinsed,
pre-treated for antigen retrieval with 0.01 M citrate buffer
(pH 5.0), again rinsed and immersed for 1 h in 0.1 M PBS
containing 0.3% Triton X-100 (PBS-T) and 10% normal
donkey serum. The sections were incubated overnight at
4C with monoclonal mouse anti-NeuN (MAB377; Milli-
pore, Schwalbach, Germany) and rat anti-CD31 (#557355;
BD Biosciences, Heidelberg, Germany) antibodies. After
detection with Cy3 or Cy2 conjugated secondary antibod-
ies, the sections were incubated with 40-6-diamidino-2-
phenylindole (DAPI) and coverslipped. For the evaluation
of DNA fragmentation, adjacent brain sections were stained
by terminal transferase dUTP nick end labeling (TUNEL)
[13, 14]. The sections were evaluated under a fluorescence
microscope (BX 41; Olympus, Hamburg, Germany) con-
nected to a CCD camera (CC12; Olympus). Surviving
NeuN ? neurons, CD31 ? microvessels and DNA-frag-
mented cells were analyzed in a blinded way by counting
numbers of cells or profiles in six defined regions of inter-
ests (ROI) per striatum measuring 62,500 lm2, both ipsi-
and contralateral to the stroke [14]. Mean values were
calculated for all areas. Striatal atrophy and corpus callosum
atrophy were assessed on sections stained with modified
Bielschowsky silver solution [6]. Thus, the borders of both
structures were outlined and their surface analyzed (in case
of corpus callosum up to 1 mm lateral to midline, thus
reflecting areas on coronal brain sections [3]).
Immunohistochemistry for CB and BDA
Brain sections of animals that had transcardially been
perfused with 4% PFA at 52 dpi were rinsed three times for
10 min each in 50 mM Tris-buffered saline (pH 8.0) con-
taining 0.5% Triton X-100 (TBST). For detection of CB,
sections were immersed overnight at 4C with polyclonal
rabbit anti-cascade blue antibody (A-5760; Invitrogen,
1:100), diluted 1:100 in 50 mM TBST, followed by
incubation for 1 h at room temperature with a horseradish
peroxidase (HRP)-labeled secondary anti-rabbit antibody
(1:1,000). For detection of BDA, the sections were incu-
bated overnight with avidin–biotin-peroxidase complex
(ABC Elite; Vector Labs). Stainings were revealed with
3,30-diaminobenzidine (DAB) containing 0.4% ammonium
sulfate and 0.004% H2O2.
Analysis of corticobulbar projections
The localization of tracer deposits was checked at the
levels of the needle tracks, thus ensuring that the motor
cortex had indeed been injected in all animals. To account
for variabilities in tracer uptake in different mice, we first
evaluated the number of tracer-stained fibers in the corti-
cospinal tract (CST) at the level of the facial nucleus. For
this purpose, two consecutive sections were analyzed,
counting the number of fibers crossing the sections in four
regions of interest of 2,865 lm2 each that had been
selected in the dorsolateral, ventrolateral, dorsomedial and
ventromedial portion of the CST. By measuring the total
area of the CST using the cell software image system
(Olympus) connected to an Olympus BX42 microscope,
we calculated the overall number of labeled pyramidal tract
fibers, as described [19, 37].
Corticobulbar projections were evaluated at the level of
the facial nucleus (bregma -5.8 to -6.3 mm). Two
500 lm long intersection lines were superimposed on the
sections parallel to the midline, both representing tangents
touching the most lateral extension of the pyramidal tract.
Along both lines those fibers crossing the lines in direction
of the contralateral and ipsilateral facial nucleus were
quantified. For each animal, the total number of fibers
counted was normalized with the number of labeled fibers
in the CST and multiplied with 100, resulting in percent
values of fibers originating from the pyramidal tract [19].
For both tracers two consecutive sections were evaluated,
of which mean values were determined.
Western blot analysis
For western blotting, tissue samples were harvested from
mice killed by decapitation at 3, 14, 30, and 42 dpi. Brains
were dissected on dry-ice. Blocks of tissue were cut from
2 mm rostral to 2 mm caudal to the bregma, from which
samples were taken from the striatum, motor cortex
and parietal cortex both ipsilateral and contralateral to
the stroke. Tissues belonging to the same hemisphere and
time-point were pooled and homogenized on ice for 30 s,
ultrasonicated for 2 min and treated with protease inhibitor
cocktail and phosphatase inhibitor cocktail. Protein content
was measured using the Bradford method. Equal amounts
of protein were loaded on 5% (NG2 proteoglycan), 7%
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(brevican) or 10% (ephrin B1, ephrin B2, c-Jun, activated
caspase-3) gels, followed by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Proteins were
transferred onto PVDF membranes (Bio-Rad, Hercules,
CA, USA) that were blocked in 5% nonfat milk in Tris-
buffered saline containing 0.1% Tween (TBS-Tw) for 1 h at
room temperature, washed in TBS-Tw and incubated
overnight with monoclonal rabbit anti-total c-Jun (#9165,
Cell Signaling), polyclonal rabbit anti-phospho-c-Jun
(#9164S, Cell Signaling), polyclonal rabbit anti-activated
caspase-3 (#9661; Cell Signaling), polyclonal rabbit anti-
NG2 proteoglycan (H-300, sc-20162; Santa Cruz, Heidel-
berg, Germany), monoclonal mouse anti-brevican (610895;
BD Biosciences), polyclonal rabbit anti-ephrin B1 (H70, sc-
20723; Santa Cruz) and polyclonal goat anti-ephrin B2
(AF496; R&D Systems, Wiesbaden, Germany) antibody,
diluted 1:1000 in TBS-Tw. The next day membranes were
washed and incubated in blocking solution with peroxidase-
conjugated secondary antibodies for 1 h at room tempera-
ture. Blots were developed using a chemiluminescence kit.
The intensity of each signal was measured on a total of three
digitized blots each using the Image J software program.
Protein loading was controlled by means of b-actin blots
using a polyclonal rabbit antibody (#4967, Cell Signaling).
The relative levels of proteins were normalized with values
determined in the contralateral striatum of animals killed at
3 dpi, i.e., the day when VEGF was administered.
Analysis of matrix metalloproteinase-9 activity
by gelatin zymography
Tissue samples from the same animals were processed for
matrix metalloproteinase-9 (MMP9) activity using a previ-
ously published gelatin zymography protocol [36]. Brain
samples were homogenized and lysed in NP-40 lysis buffer
(150 mM NaCl, 50 mM Tris–HCl, 1% NP-40, pH 8.0) con-
taining 5% protease inhibitor cocktail. Protein concentration
was estimated using the DC Protein Assay Kit using an iMark
microplate reader. Samples containing 5 lg protein were
subjected to SDS-PAGE using 8% bis-acrylamide gel con-
taining 0.1% gelatin (Sigma, Deisenhofen, Germany). After
electrophoresis, gels were incubated for 1 h at room temper-
ature in modified enzymatic activation buffer (MEAB)
(50 mM Tris–HCl, 6 mM CaCl2, 1.5 lM ZnCl2, pH 7.4)
containing 2.5% Triton X-100, followed by overnight incu-
bation in MEAB. The next day, gels were stained in coomassie
brilliant blue R-250. The gels were dried and digitized. A
number of three experiments were run for each tissue sample.
Statistical analysis
Behavioral tests were analyzed by means of two-way
repeated measurement analysis of variance (ANOVA;
treatment x time) at three different time-points starting with
3 days post-stroke, i.e., the time-point when VEGF was
administered. For those tests in which significant treatment
or treatment by time interaction effects were noticed (at
0.05 level), one-way ANOVA were done for each time-
point, using least significant differences (LSD) tests as post
hoc tests. Tract-tracing histochemistries were evaluated by
oneway ANOVA, followed by LSD tests (comparison
between n C 3 groups). Conventional histochemical sta-
inings, Western blots and gelatin zymographies were
analyzed by two-way ANOVA (treatment 9 time) or two-
tailed t-tests, as appropriate. Whenever a treatment effect
or treatment by time interaction effect was present in two-
way ANOVA at the 0.05 level, two-tailed t-tests were
performed for each time-point as post hoc tests.
Results
Neurological recovery is improved by post-acute VEGF
delivery
In order to evaluate if VEGF promotes neurological
recovery when administered in the post-acute stroke phase,
mice submitted to 30 min of left-sided MCAO were
intracerebroventricularly (i.c.v.) treated with vehicle or
VEGF (0.004 or 0.02 lg/day) starting at 3 dpi. LDF, which
was recorded to evaluate changes in cerebral blood flow
(Fig. 2a), and body weight (Fig. 2b) did not reveal any
differences between groups. Mean LDF values decreased
to 15–20% of baseline values during MCAO, followed by
stable reperfusion to levels slightly above pre-ischemic
values (Fig. 2a). Only a mild reduction in body weight was
noticed at 3 dpi in all groups (*10%), from which animals
quickly recovered within 14 dpi (Fig. 2b).
Motor recovery was investigated by grip strength
(Fig. 2c) and Rotarod (Fig. 2d) tests. Reductions in motor
force of the contralesional right forelimb (Fig. 2c) and
coordination skills (Fig. 2d) were noticed in animals sub-
mitted to 30 min MCAO. In vehicle-treated ischemic
animals and animals receiving VEGF at low dosage
(0.004 lg/day), deficits in motor force and coordination
persisted over the observation period of 6 weeks (Fig. 2c,
d). In animals treated with 0.02 lg/day VEGF, on the other
hand, grip strength and coordination skills progressively
improved during that time interval, reaching levels signif-
icantly above vehicle-treated animals at 42 dpi (Fig. 2c, d).
VEGF promotes neurovascular remodeling
To assess how VEGF affects neuronal survival, immuno-
histochemistries against the neuronal marker NeuN were
analyzed in mice receiving VEGF at the higher dosage
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(0.02 lg/day). Slowly progressive degeneration was
noticed in the ischemic striatum of vehicle-treated mice,
reflected by a loss of surviving neurons (Fig. 3a) and
progressive striatal atrophy (Fig. 3b). Notably, VEGF sig-
nificantly increased neuronal survival at 14 dpi (Fig. 3a),
translating into reduced shrinkage of the ischemic striatum
at 52 dpi (Fig. 3b).
As reported previously [23, 29], VEGF significantly
increased the density of CD31 ? brain capillaries more
strongly in the ipsilesional than contralesional striatum
(Fig. 3c). The thickness of the corpus callosum, as evalu-
ated by modified Bielschowsky stainings, was slightly, but
significantly increased by VEGF (Fig. 3d).
VEGF promotes contralesional corticobulbar plasticity
To analyze how VEGF influences pyramidal tract plastic-
ity, two dextran conjugates, CB and BDA, were
administered into both motor cortices. Injection sites were
obtained that covered the more caudal forelimb area and
rostral hindlimb area of the primary motor cortex. The
number of anterogradely labeled axons in the pyramidal
tracts did not differ between vehicle-treated and VEGF-
treated mice, neither ipsilateral nor contralateral to the
stroke (19,188 ± 7,383 vs. 25,408 ± 16,306 fibers on
lesioned side for vehicle and VEGF, respectively, at level
of facial nucleus). The area covered by the pyramidal tract
was also similar in both groups (0.05 ± 0.02 vs. 0.07 ±
0.04 mm2 on lesioned side/0.06 ± 0.01 vs. 0.07 ± 0.02
mm2 contralateral to stroke for vehicle and VEGF,
respectively), indicating that neither ischemia, nor VEGF
influenced the survival of pyramidal tract axons.
Importantly, VEGF promoted the sprouting of labeled
fibers branching off the contralesional, but not ipsilesional
pyramidal tract in direction to the facial nuclei. As such,
the number of labeled midline-crossing fibers originating
from the BDA-labeled contralesional pyramidal tract was
significantly increased, as was the number of fibers
branching off the contralesional pyramidal tract in direc-
tion of the contralesional facial nucleus (Fig. 4).
Interestingly, VEGF did not affect the plasticity of CB-
labeled ipsilesional corticobulbar fibers that was increased
Fig. 2 Delayed delivery of VEGF at 0.02 lg/day, but not 0.004 lg/
day promotes post-ischemic neurological recovery. a LDF recordings
above the core of the MCA territory, b body weight, c grip strength of
the lesion-contralateral right paretic forepaw, and d coordination
skills evaluated by RotaRod tests. Note that motor force (c) and
coordination skills (d) do not exhibit any major improvements over
time in vehicle-treated mice and mice receiving VEGF at a dosage of
0.004 lg/day, but progressively increase over 14 to 42 days in
animals treated with 0.02 lg VEGF/day. LDF recordings (a) and
body weight (b) do not differ between groups. Data are mean
values ± S.D. (n = 10 animals per group). Data were analyzed by
two-way repeated measures ANOVA, followed by one-way ANOVA/
LSD tests for each time-point. #p \ 0.05 compared with pre-ischemic
baseline, *p \ 0.05 compared with vehicle-treated ischemic mice
278 Acta Neuropathol (2012) 123:273–284
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in ischemic as compared with sham-operated non-ischemic
mice (Fig. 4).
Brain remodeling involves deactivation of matrix
metalloproteinase MMP9 in the ischemic,
but not contralesional hemisphere
To elucidate mechanisms underlying the reorganization of
the brain tissue both ipsilateral and contralateral to the
stroke, we examined the activation of MMP9 by gelatin
zymography. Activation of MMP9 was noticed throughout
the ischemic hemisphere (i.e., in striatum, parietal cortex
and motor cortex) over the observation period of 42 days
(shown for striatum in Fig. 5a). VEGF significantly atten-
uated MMP9 activity (Fig. 5a). Contralateral to the stroke,
a mild activation of MMP9 was found at 3 dpi, but not at
later time-points (not shown).
VEGF modulates the transcription factor c-Jun
and inhibits apoptotic cell death
To characterize mechanisms underlying perilesional tissue
remodeling, western blots for the transcription factor c-Jun
and the executioner caspase-3 were evaluated using anti-
bodies detecting both total and phosphorylated c-Jun as well
as cleaved (i.e., activated) caspase-3 using tissue samples
obtained from the ischemic and contralesional non-ische-
mic striatum. c-Jun was abundant in ischemic brain tissue
(Fig. 5b). Although the expression of total (i.e., phosphor-
ylated and non-phosphorylated) c-Jun was downregulated
by VEGF in the ischemic (Fig. 5b), but not non-ischemic
(not shown) striatum at 14 dpi, VEGF increased the per-
centage of phosphorylated c-Jun in the ipsilesional brain
tissue (Fig. 5b). In accordance with the promotion of neu-
ronal survival, caspase-3 activity was reduced by VEGF in
the ischemic striatum at 14 dpi (Fig. 5c), as was DNA-
fragmentation evaluated by TUNEL at 14 dpi (Fig. 5d).
VEGF-induced contralesional plasticity is accompanied
by the downregulation of growth inhibitory
proteoglycans and guidance molecules
To clarify, how VEGF influenced axonal plasticity in the
contralesional hemisphere, western blots for the axonal
growth inhibitory proteoglycans NG2 and brevican and for
the vascular and axonal guidance proteins ephrin B1 and
ephrin B2 were analyzed using tissue samples obtained
from the lesion-sided and contralesional striatum. In gen-
eral, the abundance of these four proteins was upregulated
in the subacute compared with acute phase of the stroke,
particularly at 14 and 30 dpi (Fig. 6). Intriguingly, VEGF
did not influence the expression of these proteins in the
ipsilesional striatum, which is traversed by descending
pyramidal tract axons, but reduced the abundance of NG2,
brevican and ephrin B2 in the contralesional striatum at
14 dpi (Fig. 6).
Fig. 3 VEGF promotes neurovascular histological brain remodeling.
a Density of surviving neurons in ischemic striatum evaluated by
NeuN immunohistochemistry, b striatal shrinkage examined by
Bielschowsky staining, c capillary density in ischemic striatum
assessed by CD31 immunohistochemistry and d corpus callosum
atrophy evaluated by Bielschowsky staining. Note that VEGF
increases neuronal survival at 14 dpi (a) and reduces brain atrophy
later on at 52 dpi (b). In addition, VEGF promotes angiogenesis
(c) and mildly increases corpus callosum thickness (d). Microphoto-
graphs are also shown that were taken at 14 dpi (a) or 52 dpi (b–d).
Data are mean values ± S.D. (n = 4-8 animals per group). Data were
analyzed by two-way ANOVA followed by two-tailed t-tests for
individual time-points or two-tailed t-tests, as appropriate. *p \ 0.05/
**p \ 0.01 compared with vehicle-treated ischemic mice. Bar
200 lm (b)/50 lm (c, d)/20 lm (a)
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Discussion
Using a broad set of behavioral, histochemical and molec-
ular biological techniques, which allowed us to perform a
comprehensive analysis of (a) sensorimotor recovery,
(b) secondary neurodegeneration in the perilesional tissue,
(c) angiogenesis, and (d) corticobulbar plasticity both ipsi-
and contralateral to the stroke, this study shows that VEGF
delivery promotes long distance axonal sprouting of the
contralesional pyramidal tract system and induces func-
tional neurological recovery, when delivered in the post-
acute phase of the stroke starting 3 days after focal cerebral
ischemia. That VEGF stimulates axonal plasticity has to the
best of our knowledge not been shown. Promotion of
pyramidal tract plasticity has previously been reported after
focal cerebral ischemia following deactivation of the axonal
growth inhibitor NogoA [18, 32], delivery of bone marrow-
derived stem cells [1] and erythropoietin [19].
Although we used a delayed delivery protocol, upon
which VEGF was applied starting at 72 h after the stroke,
VEGF promoted structural histological brain remodeling.
As such, VEGF protected the brain against delayed neu-
ronal death at 14 dpi, inhibiting caspase-3-dependent
apoptotic injury, and prevented post-acute tissue shrinkage
at 30 and 52 dpi. Besides, VEGF enhanced angiogenesis in
the brain of VEGF-treated mice, as investigated in this
study at 52 dpi. The attenuation of brain atrophy highlights
the importance of protracted reorganization processes,
which continue to progress over several weeks [3, 19].
Delayed neurodegeneration and brain atrophy have previ-
ously been reported to be reversed by delivery of neural
precursor cells [3] and erythropoietin [19], when these
neural precursor cells or erythropoietin were used in a
similarly delayed time window. Post-ischemic neuropro-
tection and angiogenesis have repeatedly been described
after acute VEGF delivery [11]. Neuroprotection was
noticed as long as the growth factor was locally adminis-
tered at post-acute time-points (1–3 days post ischemia)
[23] or constitutively overexpressed in the brain but not the
rest of the body [29], whereas systemic delivery was found
Fig. 4 VEGF promotes contralesional, but not ipsilesional cortico-
bulbar plasticity. Tract-tracing analysis at the level of the facial
nucleus (FN) in mice receiving cascade blue (CB) and biotinylated
dextran amine (BDA) injections into the lesion-sided and contrale-
sional motor cortex (for placement of tracer injections see (a)).
Percent of fibers leaving the pyramidal tract in direction to the
ipsilesional and contralesional FN traced by (b) CB and (c) BDA.
Note that the percentage of fibers projecting to the ipsilesional FN
after CB injection into the lesion-sided motor cortex significantly
increases in response to stroke (b). Interestingly, VEGF does not
further strengthen this ipsilesional projection (b), but increases the
percentage of BDA stained contralesional pyramidal tract fibers
innervating the ipsilesional and contralesional FN (c). d Microphoto-
graphs of representative ischemic vehicle-treated and VEGF-treated
mice showing BDA-traced corticobulbar fibers crossing the intersec-
tion lines (superimposed in blue) on both sides of the brain. Note that
VEGF increases axonal sprouting towards both FN (intersecting fibers
labeled with dots). Data are means ± S.D. (n = 10 animals per group
(ischemic vehicle, ischemic VEGF)/n = 4 animals per group (non-
ischemic vehicle)). Data were analyzed by one way ANOVA
followed by LSD tests. #p \ 0.05 compared with vehicle-treated
non-ischemic mice. *p \ 0.05 compared with vehicle-treated ische-
mic mice
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to exacerbate brain edema and neuronal injury when
applied at early (1 h post ischemia) but not at late (48 h)
time-points [34], thus pointing out a double-edged role of
VEGF in the ischemic brain. The neuroprotective effect of
VEGF involves the release of neurotrophic growth factors
from cerebral microvascular cells [35] as well as direct
neurotrophic effects of VEGF [15, 31].
Since VEGF promoted neuronal survival and angio-
genesis, the question arose whether this enhanced
neurovascular remodeling is accompanied by long-distance
axonal plasticity in the ischemic hemisphere. Joint
responses of vessels and axons to VEGF exposure could be
expected based on observations during ontogeny, where
angiogenesis and neuronal sprouting are closely linked.
Throughout the periphery of the body, blood vessels and
peripheral nerves share joint nerve and vessel sheaths,
being navigated by very similar and partly overlapping
growth and guidance cues [10]. Examples are members of
the slit and semaphorin families that are involved in blood
vessel and nerve guidance [2]. That axonal sprouting and
angiogenesis were not jointly regulated by VEGF after
stroke, like angiogenesis and neuronal survival, but
spatially segregated from each other indicates that the
responses of the adult CNS to injury differ from peripheral
nerve-vessel systems.
In the induction of post-ischemic angiogenesis, MMPs,
namely MMP9, play a crucial role. MMP9 contributes to
the breakdown of the ECM, which prepares the stage for
vascular growth. Following acute VEGF delivery, MMP9
activity increases in the perilesional ischemic tissue, clo-
sely in line with leaky vessels that are formed [26]. The
brain response to chronic VEGF differs from acute VEGF
delivery, as we now showed, since MMP9 was inhibited
instead of activated by the growth factor. The deactivation
of MMP9 may reflect the maturation of newly formed brain
vessels. MMP9 has not only been involved in angiogenesis,
but also in axonal remodeling and repair. By cleaving
growth inhibitory proteins, such as the proteoglycan NG2,
MMP9 was suggested to promote axonal myelination. As
such, impaired remyelination was observed in MMP9
deficient mice in a model of lysolecithin-induced demye-
lination [16], which was interpreted as a consequence of
the lack of proteoglycan proteolysis. It is conceivable that
the deactivation of MMP9 contributed to the lack of axonal
Fig. 5 VEGF deactivates MMP9, activates c-Jun and prevents
caspase-3-dependent apoptotic cell death. Gelatin zymography for
MMP9 (a), Western blot analysis using antibodies detecting total and
phosphorylated c-Jun (b) and cleaved (i.e., activated) caspase-3 (c), as
well as DNA fragmentation studies using TUNEL (d). For studies in
(a)–(c), tissue samples obtained from the striatum were used. In
(b) and (c), data are presented as optical densities. Protein loading
was controlled with a b-actin antibody. Representative zymographies,
blots and TUNEL stainings are shown. Data are means ± SD (n = 3
zymographies and western blots (a)–(c)/n = 4 animals per group).
Data were analyzed by two-way ANOVA followed by two-tailed
t-tests for individual time-points. **p \ 0.01 compared with vehicle-
treated ischemic mice. Bar 45 lm
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sprouting in the lesioned hemisphere by preventing the
degradation of growth-inhibitory glycoproteins, thus
resulting in a reduced permissiveness of the ECM for
growing axons. That the breakdown of ECM glycoproteins
by MMP9 is indeed required so that successful brain
remodeling may take place, has already been shown by
Zhao et al. [36] in rats submitted to focal cerebral ischemia.
In their study, the authors prevented ECM breakdown by
means of MMP inhibitors and observed increased brain
injury, disturbed angiogenesis and impaired neurological
recovery.
With respect to the axonal plasticity contralateral to the
stroke, the transient downregulation of the axonal growth
inhibitors NG2 and brevican and of the guidance molecules
ephrin B1 and ephrin B2 in the contralesional hemisphere
offers important clues. Ephrins, namely ephrin B2, are
required for developmental as well as tumor-associated
angiogenesis, promoting the internalization of VEGF
receptors, namely VEGFR2 that mediates angiogenesis,
into cells [20, 28]. Internalization of VEGFR2 is necessary
for activation and downstream signaling of the receptor and
is needed for the VEGF-induced extension of the cells,
which sets the stage for vessel sprouting [20]. Intriguingly,
the effects of ephrins on axons differ from those on vessels.
During development, ephrins may have attractant and
repellent properties, depending on their site of action and
Fig. 6 VEGF downregulates
growth inhibitory proteoglycans
and guidance molecules in the
contralesional hemisphere.
Western blot analysis using
antibodies detecting total NG2
proteoglycan (a, b), brevican (c,
d), ephrin B1 (e, f) and ephrin
B2 (g, h), both for the ischemic
and contralesional non-ischemic
striatum. Note the
downregulation of the
proteoglycans and guidance
molecules in the contralesional
non-ischemic striatum at 14 dpi.
Data were normalized with
values determined in the
contralateral striatum of animals
submitted to focal cerebral
ischemia followed by 3 days
reperfusion. Protein loading was
controlled with a b-actin
antibody. Representative blots
are shown. Data are
means ± SD (n = 3 western
blots). Data were analyzed by
two-way ANOVA followed by
two-tailed t-tests. *p \ 0.05/
**p \ 0.01 compared with non-
ischemic vehicle
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the coexpression of ephrin receptors [12]. In the adult
brain, on the other hand, the primary role of ephrins in
regeneration is repulsive [10]. From this perspective, the
downregulation of ephrin B2 and ephrin B1 similar as that
of NG2 and brevican may have created a favorable envi-
ronment, in which pyramidal tract plasticity became
possible. Further studies will be necessary to better delin-
eate the structural, molecular and functional processes
underlying lesion-remote plasticity after stroke.
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